Core Viewpoint - Novo Nordisk is planning to explore in clinical trials whether its future weight-loss drugs can address a variety of health conditions associated with obesity, building on its existing successful products [1] Group 1: Company Initiatives - The company has already initiated trials with its blockbuster weight-loss drug to assess its effectiveness in treating obesity-related health issues [1] Group 2: Industry Implications - The exploration of weight-loss drugs for broader health applications could signify a shift in the pharmaceutical industry towards addressing obesity as a multifaceted health concern [1]